Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|December 19, 2011
IRB Services Awarded Full Accreditation for Protecting Research Participants
Advertisement
IRB Services is the first fully independent, unaffiliated Canadian-based research ethics committee to earn Accreditation from AAHRPP.
AAHRPP accreditation—which translates into significant benefits for research participants and society as a whole—is available to US and international organizations that conduct biomedical, behavioral or social sciences research involving human participants.
Founded in 1993, IRB Services is an independent organization dedicated to protecting the rights and safety of human subjects. IRB Services operates research ethics committees in Toronto, Ontario; Montreal, Quebec; and Boca Raton, Florida, which review a wide range of bothindustry and publicly funded human subject research across multiple disciplines, including Health Canada, Food and Drug Administration, and US Department of Health and Human Services regulated research.
“Since IRB Services operates in an international environment with geographically-dispersed ethics committees dealing with a complex matrix of regulatory and ethical requirements, AAHRPP’s accreditation process has ensured the company meets or exceeds all those obligations and more,” said Jack Corman, President and CEO of IRB Services.
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that Human Research Protection Programs (HRPP) meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence-through policies, procedures, and practices—of their commitment to scientifically and ethically sound research and to continuousimprovement. As the "gold seal," AAHRPP accreditation offers assurances—to research participants, researchers, sponsors, government regulators, and the general public—that an HRPP is focused first and foremost on excellence.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5